About the Company

上海澳宗生物科技有限公司是一家专注于神经系统CNS领域的新药开发公司,成立于2017年,总部位于中国上海,目前在美国纽约、澳大利亚悉尼和中国北京、重庆设有全资子公司。公司在研管线布局阿尔兹海默症(AD)、孤独症(ASD)、急性缺血性脑卒中(AIS)、肌萎缩侧索硬化症(ALS)、帕金森(PD)和抗衰老等神经系统疾病。公司目前拥有3大品种、10余条管线的研发项目,首推核心项目TTYP01是全球*的依达拉奉口服片剂,已有2个适应症管线分别在中美两国完成关键性临床,并已提交新药上市申请(NDA),同时,正在推进3个适应症管线的国内国际Ⅱ/Ⅲ期临床试验以及其他后续管线的开发。

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Related Industry Tags

Tags are auto-annotated by keyword text matching and may be correlated. For reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 3,781.74万(元)
Legal Representative: 周意
Date Established:
Credit Code: 91320594MA1Q44HM3H
Registered Address: 上海市杨浦区杨树浦路1366号名义楼层19层19-1室(实际楼层16层)

People who follow this company also follow

Competitors (Similar Companies)

生命科学仪器 激光 实验仪器设备 激光技术
临床研究 临床试验 药物研发外包 神经治疗
金融 风险监控 金融风险管理 创新服务
抗体 药物研发 创新药 研发
医药 生物制品 生物医药 医疗科技

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates